drugset / Trial / NCT01216826
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed osteosarcoma. The aim response is defined as complete or partial response (according to RECIST criteria) for at least 4 weeks, or stable disease for at least 12 weeks.
Timeline
- Start
- 2011-03
- Primary completion
- 2014-06
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg/m2 | — |
| Subject | Everolimus | Small molecule | 10 mg | — |
Indications
No indication recorded.